SBUX

In October, Starbucks will stop covering GLP-1 drugs prescribed for weight loss for benefits-eligible employees. The move comes as GLP-1 drugs consume a growing share of employers' healthcare spending.

In early 2011, Starbucks (NASDAQ:SBUX | SBUX Price Prediction) marked its 40th birthday by stripping the wordmark from its logo, leaving only the green siren.

A rebound in traffic at Starbucks is driving a recovery in its earnings power. The demand for customizable energy drinks continues to drive growth for both coffee chains.

Starbucks is bringing back its Pumpkin Spice Latte this month and adding new fall drinks, food items and merchandise to its seasonal lineup.

SBUX raised its fiscal 2026 outlook after stronger sales and margins, but lasting earnings gains still hinge on sustaining growth and managing costs.

SBUX shows stronger sales, traffic and earnings as management lifts fiscal 2026 outlook, but its premium valuation keeps the turnaround under close watch.

Starbucks raises its fiscal 2026 outlook as broader traffic gains, faster service and store upgrades strengthen its turnaround.

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Starbucks is executing a successful turnaround, with accelerating global comparable sales and expanding operating margins. The company raised FY2026 guidance for comp. sales growth and EPS, reflecting robust business momentum and strategic execution. Cost efficiency initiatives, including AI-driven software savings and a shift to higher-margin licensing, are supporting profitability improvements.

Chipotle and Starbucks saw better-than-expected same-store sales last quarter. The opportunity to recapture lost operating margin could be a big driver for Starbucks stock.